Literature DB >> 20054554

Level IIb lymph node metastasis in thyroid papillary carcinoma.

Yusuf Vayisoglu1, Cengiz Ozcan, Ozgur Turkmenoglu, Kemal Gorur, Murat Unal, Ahmet Dag, Koray Ocal.   

Abstract

The objective of the study was to evaluate the incidence of level IIb lymph node metastases in neck dissections for thyroid papillary carcinoma (TPC) patients. 47 neck dissections of 33 patients with TPC were prospectively evaluated. Selective neck dissections (levels II, III, IV, and V) were performed in all cases. If level I lymph node metastasis was suspected during the procedure, level I dissection was also performed. All level IIb specimens were sent separately from the remainder of the neck dissection for the pathological examination. The number of dissected and metastatic lymph nodes in each specimen was recorded. Twenty-two of 47 neck dissections (46.8%) were positive for the lymph node metastasis. Among 47 neck dissection specimens, the incidence of lymph node metastasis at level II was 12.7% (6 of 47) and level IIb was 2.1% (1 of 47). The rate of level IIb lymph node involvement among patients with metastatic cervical lymph nodes was 4.5% (1 of 22). The specimen with metastatic lymph node at level IIb had also metastasis at levels IIa, III, IV, and V. The results of the present study suggested that lymph node metastases in level IIb are rare in patients with TPC undergoing neck dissection.

Entities:  

Mesh:

Year:  2010        PMID: 20054554     DOI: 10.1007/s00405-009-1185-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  29 in total

1.  Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery.

Authors:  K Thomas Robbins; Garry Clayman; Paul A Levine; Jesus Medina; Roy Sessions; Ashok Shaha; Peter Som; Gregory T Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-07

2.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Steven I Sherman; R Michael Tuttle
Journal:  Thyroid       Date:  2006-02       Impact factor: 6.568

3.  Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma.

Authors:  Bon Seok Koo; Eun Chang Choi; Yeo-Hoon Yoon; Dong-Hyun Kim; Eung-Hyub Kim; Young Chang Lim
Journal:  Ann Surg       Date:  2009-05       Impact factor: 12.969

4.  Patterns of metastases to the upper jugular lymph nodes (the "submuscular recess").

Authors:  Y P Talmi; H T Hoffman; Z Horowitz; T M McCulloch; G F Funk; S M Graham; M Peleg; R Yahalom; S Teicher; J Kronenberg
Journal:  Head Neck       Date:  1998-12       Impact factor: 3.147

5.  Prevalence of nodal metastases in the submuscular recess (level IIb) during selective neck dissection.

Authors:  Damon A Silverman; Michel El-Hajj; Scott Strome; Ramon M Esclamado
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-07

6.  Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.

Authors:  Ashok R Shaha
Journal:  Laryngoscope       Date:  2004-03       Impact factor: 3.325

7.  Predictive factors of level IIb lymph node metastasis in patients with papillary thyroid carcinoma.

Authors:  Bon Seok Koo; Yeo-Hoon Yoon; Jin-Man Kim; Eun Chang Choi; Young Chang Lim
Journal:  Ann Surg Oncol       Date:  2009-02-18       Impact factor: 5.344

8.  Regional metastases in well-differentiated thyroid carcinoma: pattern of spread.

Authors:  Yoav Yanir; Ilana Doweck
Journal:  Laryngoscope       Date:  2008-03       Impact factor: 3.325

9.  Papillary thyroid cancer: controversies in the management of neck metastasis.

Authors:  H Carter Davidson; Brian J Park; Jonas T Johnson
Journal:  Laryngoscope       Date:  2008-12       Impact factor: 3.325

10.  Is level IIb lymph node dissection always necessary in N1b papillary thyroid carcinoma patients?

Authors:  Jandee Lee; Tae-Yon Sung; Kee-Hyun Nam; Woung Youn Chung; Euy-Young Soh; Cheong Soo Park
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

View more
  7 in total

Review 1.  Individualized optimal surgical extent of the lateral neck in papillary thyroid cancer with lateral cervical metastasis.

Authors:  Jae-Yong Park; Bon Seok Koo
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-16       Impact factor: 2.503

2.  Level I lymph node involvement in patients with N1b papillary thyroid carcinoma: a prospective study.

Authors:  Ahmad M Eweida; Mahmoud F Sakr; Yasser Hamza; Mohamed R Khalil; Essam Gabr; Tarek Koraitim; Hatem F Al-Wagih; Waleed Abo-Elwafa; Tarek Ezzat Abdel-Aziz; Ahmed A Diab; Basma El-Sabaa; Aman S Nabawi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-20       Impact factor: 2.503

Review 3.  The extent of lateral lymph node dissection in differentiated thyroid cancer in the N+ neck.

Authors:  S Kumar; C Burgess; R Moorthy
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-22       Impact factor: 2.503

4.  The efficacy of lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma.

Authors:  Se Kyung Lee; Sung Hoon Kim; Sung Mo Hur; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 5.  Involvement of level IIb lymph node metastasis and dissection in thyroid cancer.

Authors:  Yusuf Vayisoglu; Cengiz Ozcan
Journal:  Gland Surg       Date:  2013-11

6.  Risk factors for level V metastasis in patients with N1b papillary thyroid cancer.

Authors:  Jin Gu Kang; Jung Eun Choi; Su Hwan Kang
Journal:  World J Surg Oncol       Date:  2022-09-30       Impact factor: 3.253

Review 7.  Level V Clearance in Neck Dissection for Papillary Thyroid Carcinoma: A Need for Homogeneous Studies.

Authors:  Azhar Jan Battoo; Zahoor Ahmad Sheikh; Krishnakumar Thankappan; Abdul Wahid Mir; Altaf Gowhar Haji
Journal:  Int Arch Otorhinolaryngol       Date:  2017-12-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.